Please assess the completion status of the following clinical trial:

Trial Title: A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria :~* Two month old infants (55 to 65 days old) on the day of inclusion.~* Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg.~* Informed consent form signed by one or both parents or by the legally acceptable representative as per local requirements.~* Able to attend all scheduled visits and to comply with all trial procedures.~* Received Hepatitis B and Bacille de Calmette-Guérin (BCG) vaccines between birth and one month of life in agreement with the national immunization calendar.~Exclusion Criteria :~* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy, or long-term systemic corticosteroid therapy.~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances.~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.~* Blood or blood-derived products received since birth that might interfere with the assessment of the immune response.~* Any vaccination before trial vaccination (except Hepatitis B and Bacille de Calmette Guérin given at birth).~* Any planned vaccination until 1 month after the last trial vaccination (except the study vaccines, rotavirus and pneumococcal conjugated vaccines).~* Documented history of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b or Hepatitis B infection(s) (confirmed either clinically, serologically or microbiologically).~* Previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, or Haemophilus influenzae type b infections.~* Known personal or maternal history of Human Immunodeficiency Virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C seropositivity.~* Known coagulopathy, thrombocytopenia or a bleeding disorder preceding inclusion contraindicating intramuscular (IM) vaccination.~* History of seizures or encephalopathy.~* Febrile illness (temperature ≥ 38.0°C), or moderate or severe acute illness/infection on the day of inclusion, according to the Investigator judgment.

- Gender: ALL
- Minimum Age: 55 Days
- Maximum Age: 65 Days
- Healthy Volunteers: t

Study Arms:
- Group 1: DTaP-IPV-Hep B-PRP-T (Lot A) (Type: EXPERIMENTAL): None
- Group 2: DTaP-IPV-Hep B-PRP-T (Lot B) (Type: EXPERIMENTAL): None
- Group 3: DTaP-IPV-Hep B-PRP-T (Lot C) (Type: EXPERIMENTAL): None
- Group 4: Active Control (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete